Key Takeaways
- All-time high revenue, sixth straight quarter of EBITDA growth: The quarter delivered record top line and continued absolute EBITDA expansion, with gross margins near 60% and a more disciplined US pricing environment.
- US business targeting $400 million within two years: New launches are landing in the $15–$20 million range, well above historical sizes, and management is confident the approved pipeline can carry the business to that milestone while preserving margins.
- OneSource CDMO separation unlocks a hidden $160 million business: The carve-out, expected to close this quarter, moves roughly ₹150 crores of EBITDA off Strides' P&L, yet management still stands by its existing EBITDA guidance, implying like-to-like EBITDA closer to ₹950 crores next year.
- Network cleanup is done: The Singapore facility sale and Pondicherry warning letter closure remove the last structural overhangs; the one-off hit from Singapore delivers roughly ₹70 crores of annual margin improvement from EBITDA to PAT.
- What to watch next quarter: Whether the Syngene transaction closes on schedule, the pace of new US product launches, and any early revenue signals from the GLP-1 CDMO order book.
US Business: The $400 Million Roadmap
- Milestone and timeline: Management sees $400 million as the right size to sustain current US margins, and expects to reach it within two financial years, backed entirely by already-approved products.
- Why new launches are bigger: Recent approvals sit in the $15 million to $20 million range, roughly triple the historical $5 million to $7 million, which is why US growth will accelerate while other markets grow more steadily.
- Calibrated discipline: Beyond $400 million, management may deliberately cap US growth because further scale could impair the margin profile it wants to protect.
- Pricing environment: More disciplined across both buyers and sellers, supported by product shortages and a niche portfolio where over 30 products hold top 1–2 market share positions, though isolated irrational pricing has not fully disappeared.
- Near-term catalysts: A critical product approval and generic Vascepa are launching this quarter; 3–4 products with $20 million-plus exit run rates expected by year-end.
Arun Kumar: "I am saying that if we want to do a calibrated disciplined approach for the US business, in spite of us having so much of approved pipeline, we will believe that $400 million is the right size for us to keep the margin profile that we currently achieve in the US, and also to have a backup when we are challenged on certain products."
OneSource CDMO & the GLP-1 Opportunity
- Carve-out economics: OneSource is expected to launch at roughly $160 million in revenue next year, post-NCLT, and management targets $400 million by FY27. About ₹150 crores of EBITDA will move with it, yet Strides reaffirms its standalone EBITDA guidance, implying like-to-like EBITDA of roughly ₹950 crores next year.
- Stelis GLP-1 order book: The associate company already serves about 15 customers and has filed weight-loss and diabetic drugs in drug-device formats. Development and filing batches are complete, and manufacturing has begun for customers with regulatory filings underway.
- Revenue trajectory: R&D income and a large order book exist now, but commercial supply patterns begin only partially in FY25, with the main wave not starting until 2030 when key patents expire. Peak revenue across GLP programs is pegged at $300 million, contingent on partner approvals and the patent regime.
- Confidentiality constraints: Management declined to quantify liraglutide sales or estimate market share for its CDMO customers, citing partner confidentiality commitments.
Other Regulated & Growth Markets
- Other regulated markets: Performance was stellar, driven by continued growth in Australia, the Nordics, and a significant uptick in continental Europe following the complete shift to a B2B model.
- Long-term ambition: Management wants these markets to eventually mirror the US at $400 million, but that will take roughly 4 to 4.5 years, and it declined to provide near-term growth guidance, calling it too early.
- Growth and access markets: Starting to show results, with increased focus on new geographies and portfolios; management expects these to become as important as regulated markets within 2 to 3 years.
Balance Sheet & Cost Structure
- Debt reduction on track: Net debt to EBITDA improved from 5.3x in FY23 to 3.3x in H1 FY24, driven by free cash generation, a reduced cash-to-cash cycle, and Singapore sale proceeds. The target is under 3x this year and much below 2x within two years.
- Singapore cleanup: The mothballed facility was sold at a one-time loss, removing roughly ₹70 crores of annual drag from EBITDA to PAT and improving ROCE. Management framed this as the final step to remove all overhangs for the next 3–4 years.
- OPEX ceiling: Management does not expect OPEX to exceed $200 million for several years, citing cost focus, optimization, and plant-level OEE improvements.
- Working capital: Inventory days target a further 15-day reduction from the current 127, supporting 15–16% top-line growth without incremental working capital strain.
- One-off personnel cost: A policy change cut variable pay for some employees but added it back to CTCs, creating a one-off hit. The new steady-state quarterly base is roughly ₹185 crores.
Arun Kumar: "We don't believe our OPEX levels are going to increase greater than $200 million for several years. And that is because of our very keen focus on costs and also a lot of things that we do in terms of optimization, OPEX leverage, and OEE improvements in our plants."
Margins & Profitability
- Gross margin: Close to 60%, which management calls almost an industry high given the absence of a domestic business.
- EBITDA walk: Despite roughly ₹150 crores of EBITDA transferring to OneSource, Strides reaffirms it will still achieve its current EBITDA, meaning the like-to-like number next year approaches ₹950 crores.
- Stelis drag fading: Losses from the Stelis JV will be negligible in H2, and the business is expected to turn EBITDA positive.
- Other income clarification: The ₹26.9 crore shown as other income is IP income in the normal course of business, not a one-off.
Arun Kumar: "We firmly stand by our guidance that in spite of about 150 crores of EBITDA moving to OneSource, we will still achieve our current EBITDA. So, effectively, we are telling you that like to like, our EBITDA will be closer to 950 crores in the next year."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US revenue | $240 million to $250 million; confident of higher end | FY24 |
| US business milestone | Closer to $400 million | Within 2 financial years |
| Net debt to EBITDA | Under 3x | FY24 |
| Net debt to EBITDA | Much below 2x | Within 2 years |
| OneSource CDMO revenue | Approximately $160 million at launch, $400 million target | Launch year post-NCLT; FY27 |
| Stelis JV losses | Negligible in H2; business turns EBITDA positive | H2 FY24 |
| Syngene transaction close | Expected this quarter | Current quarter |
| OPEX ceiling | Not to exceed $200 million | For several years |
| Like-to-like EBITDA | Closer to ₹950 crores | Next year |
| Inventory days | Reduce by another 15 days from 127 | Not specified |
| Top-line growth | 15% to 16% without incremental working capital | Not specified |
| Other regulated markets mirror US | $400 million | Probably 4 to 4.5 years |
| US growth cap | May not grow beyond $400 million to protect margins | After $400 million milestone |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | All-time high, business grew 16% |
| Gross margin | Close to 60%, almost industry high considering no domestic business |
| EBITDA | Sixth consecutive quarter of absolute EBITDA growth |
| Other income | ₹26.9 cr, income earned on IPs in normal course of business, not a one-off |
| Net debt to EBITDA | ~3.3x, improved from 5.3x at FY23 end and ~8x at FY22 start |
| Net debt reduction | ₹62 cr from Singapore sale proceeds |
| Cash-to-cash cycle | Just under 125–126 days, reduced by ~30 working days from FY22 |
| US revenue guidance FY24 | $240 mn to $250 mn, confident of achieving higher end of $250 mn |
| US business exit run rate | Close to $270 mn to $280 mn |
| US business milestone | $400 mn, not later than 2 financial years from now |
| Other regulated markets exit run rate | ~$200 mn, almost 50% growth in last 2 years |
| OPEX levels | Not greater than $200 mn for several years |
| Personal cost new base | ₹185 cr, steady state going forward except standard annual increases |
| One-off cost increase in other OPEX | ₹15 cr, related to variable pay policy change for employees |
| Singapore facility sale margin improvement | Close to ₹70 cr from EBITDA to PAT |
| Like-to-like EBITDA guidance next year | Closer to ₹950 cr, in spite of ~₹150 cr EBITDA moving to OneSource |
| CDMO business (OneSource) launch year revenue | About $160 mn, next year after NCLT process |
| CDMO business (OneSource) FY27 target | $400 mn |
| GLP-1 peak revenues | About $300 mn, dependent on partner approvals and patent regime |
| Products with $20 mn+ exit run rates | 3–4 products by end of year |
| Icosapent product opportunity | About $20 mn by default of market size |
| Average product range | More than $10 mn to $12 mn, up from $4 mn–$5 mn historically |
| Inventory days | 127 days, down from 150-odd days; target to reduce by another 15 days |
| Top line growth expectation | 15% to 16% without worrying about incremental working capital |
| Targeted debt reduction Strides plus Stelis | About ₹700 cr |
| Debt to EBITDA target next 2 years | Much below 2 |